{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:13:16Z","timestamp":1790957596778,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.phrs.2011.01.001","type":"journal-article","created":{"date-parts":[[2011,1,6]],"date-time":"2011-01-06T09:15:59Z","timestamp":1294305359000},"page":"284-293","source":"Crossref","is-referenced-by-count":71,"title":["EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db\/db mice and prolongs the survival of stroke-prone rats"],"prefix":"10.1016","volume":"63","author":[{"given":"Wenbin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajith","family":"Welihinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Mechanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangcheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelin","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binhua","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques Y.","family":"Roberge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Seed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2011.01.001_bib0005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/CS20060150","article-title":"Diet, obesity and diabetes: a current update","volume":"112","author":"Walker","year":"2007","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.phrs.2011.01.001_bib0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jama.291.3.335","article-title":"Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes","volume":"291","author":"Saydah","year":"2004","journal-title":"Jama"},{"key":"10.1016\/j.phrs.2011.01.001_bib0015","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2014a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.phrs.2011.01.001_bib0020","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The human kidney low affinity Na+\/glucose cotransporter SLGT2. Delineation of the major renal reabsorptive mechanism for d-glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.phrs.2011.01.001_bib0025","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","article-title":"Renal Na(+)-glucose cotransporters","volume":"280","author":"Wright","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.phrs.2011.01.001_bib0030","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1006\/geno.1993.1411","article-title":"Localization of the Na+\/glucose cotransporter gene SGLT2 to human chromosome 16 close to the centromere","volume":"17","author":"Wells","year":"1993","journal-title":"Genomics"},{"key":"10.1016\/j.phrs.2011.01.001_bib0035","doi-asserted-by":"crossref","first-page":"29365","DOI":"10.1074\/jbc.270.49.29365","article-title":"Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney","volume":"270","author":"You","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2011.01.001_bib0040","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2011.01.001_bib0045","doi-asserted-by":"crossref","first-page":"14669","DOI":"10.1074\/jbc.M212240200","article-title":"Cloning and characterization of a novel Na+-dependent glucose transporter (NaGLT1) in rat kidney","volume":"278","author":"Horiba","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2011.01.001_bib0050","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.lfs.2004.10.016","article-title":"SLC5A9\/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-d-glucitol, and fructose","volume":"76","author":"Tazawa","year":"2005","journal-title":"Life Sci"},{"key":"10.1016\/j.phrs.2011.01.001_bib0055","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1242\/jeb.196.1.197","article-title":"\u2018Active\u2019 sugar transport in eukaryotes","volume":"196","author":"Wright","year":"1994","journal-title":"J Exp Biol"},{"key":"10.1016\/j.phrs.2011.01.001_bib0060","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1385\/CBB:36:2-3:115","article-title":"Molecular basis for glucose\u2013galactose malabsorption","volume":"36","author":"Wright","year":"2002","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.phrs.2011.01.001_bib0065","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00439-003-1054-x","article-title":"Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria","volume":"114","author":"Calado","year":"2004","journal-title":"Hum Genet"},{"key":"10.1016\/j.phrs.2011.01.001_bib0070","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1093\/ndt\/gfh366","article-title":"Long-term outcome of renal glucosuria type 0: the original patient and his natural history","volume":"19","author":"Scholl-Burgi","year":"2004","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.phrs.2011.01.001_bib0075","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/sj.ki.5000194","article-title":"Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting","volume":"69","author":"Calado","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.phrs.2011.01.001_bib0080","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2337\/diabetes.48.9.1794","article-title":"T-1095, an inhibitor of renal Na+glucose cotransporters, may provide a novel approach to treating diabetes","volume":"48","author":"Oku","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2011.01.001_bib0085","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejphar.2009.03.007","article-title":"Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats","volume":"609","author":"Fujimori","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.phrs.2011.01.001_bib0090","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/jpet.108.140210","article-title":"Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models","volume":"327","author":"Fujimori","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2011.01.001_bib0095","first-page":"A143","article-title":"JNJ-28431754\/TA-7284, an SGLT inhibitor, lowers blood glucose and reduces body weight in obese and type 2 diabetic animal models","volume":"58","author":"Liang","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2011.01.001_bib0100","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2011.01.001_bib0105","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","article-title":"Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"51","author":"Meng","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.phrs.2011.01.001_bib0110","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1016\/j.bmcl.2008.07.109","article-title":"Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2","volume":"18","author":"Ellsworth","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.phrs.2011.01.001_bib0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: a review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diab Metabol Res Rev"},{"key":"10.1016\/j.phrs.2011.01.001_bib0120","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1248\/cpb.44.1174","article-title":"Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4\u2032-dehydroxyphlorizin derivatives based on a new concept","volume":"44","author":"Tsujihara","year":"1996","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.phrs.2011.01.001_bib0125","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.106.110296","article-title":"Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level","volume":"320","author":"Katsuno","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2011.01.001_bib0130","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/sj.bjp.0703829","article-title":"Improved diabetic syndrome in C57BL\/Ksj-db\/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095","volume":"132","author":"Arakawa","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2011.01.001_bib0135","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/en.2007-1088","article-title":"Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity","volume":"149","author":"Freitas","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2011.01.001_bib0140","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2011.01.001_bib0145","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.2337\/diabetes.53.suppl_3.S151","article-title":"Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview","volume":"53","author":"Melander","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2011.01.001_bib0150","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-Jarvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2011.01.001_bib0155","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium\u2013glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diab Care"},{"key":"10.1016\/j.phrs.2011.01.001_bib0160","first-page":"541","article-title":"Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats","volume":"23","author":"Osorio","year":"2010","journal-title":"J Nephrol"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661811000041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661811000041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:26:26Z","timestamp":1637108786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661811000041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S1043661811000041"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2011.01.001","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}